Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 8/2015

Open Access 01-08-2015 | Nuclear Cardiology (V Dilsizian, Section Editor)

PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis

Authors: Matthias Bauwens, Felix M. Mottaghy, Jan Bucerius

Published in: Current Cardiology Reports | Issue 8/2015

Login to get access

Abstract

During the past years, non-neuronal vascular nicotinic acetylcholine receptors (nAChRs) increasingly have gained interest in cardiovascular research, as they are known to mediate the deleterious effects of nicotine and nitrosamines, components of tobacco smoke, on the vasculature. Because smoking is a major risk factor for the development of atherosclerosis, it is obvious that understanding the pathophysiologic role of nAChRs in the atherosclerotic disease process, as well as in the development of new diagnostic and therapeutic nAChR-related options, has become more important. Accordingly, we briefly summarize the pathophysiologic role of vascular nAChRs in the atherosclerotic disease process. We also provide an overview of currently available nAChR positron emission tomography (PET) tracers and their performance in the noninvasive imaging of vascular nAChRs, as well as potential nAChR PET tracers that might be an option for vascular nAChR PET imaging in the future.
Literature
1.
Tarkin JM, Rudd JH. Techniques for noninvasive molecular imaging of atherosclerotic plaque. Nat Rev Cardiol. 2014;12(2):79.PubMedCrossRef
2.
Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2950–9.PubMedCrossRef
3.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
4.••
Santanam N, Thornhill BA, Lau JK, et al. Nicotinic acetylcholine receptor signaling in atherogenesis. Atherosclerosis. 2012;225(2):264–73. This recent review of nAChRs in atherosclerosis summarizes the proatherogenic effects mediated by vascular nAChRs and discusses the pathophysiologic effects of different nAChR subunits in plaque growth, progression, and neovascularization.PubMedCrossRef
5.
Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140(2):301–16.PubMedCentralPubMed
6.
Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol. 2007;49(21):2073–80.PubMedCrossRef
7.
Egleton RD, Brown KC, Dasgupta P. Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacol Ther. 2009;121(2):205–23.PubMedCrossRef
8.
Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol. 1997;15(2):193–222.PubMedCrossRef
9.
Itier V, Bertrand D. Neuronal nicotinic receptors: from protein structure to function. FEBS Lett. 2001;504(3):118–25.PubMedCrossRef
10.
Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004;74(6):363–96.PubMedCrossRef
11.
Lukas RJ. Heterogeneity of high-affinity nicotinic [3H]acetylcholine binding sites. J Pharmacol Exp Ther. 1990;253(1):51–7.PubMed
12.
Glowatzki E, Fuchs PA. Cholinergic synaptic inhibition of inner hair cells in the neonatal mammalian cochlea. Science. 2000;288(5475):2366–8.PubMedCrossRef
13.
Schmaljohann J, Gundisch D, Minnerop M, et al. A simple and fast method for the preparation of n.c.a. 2-[18F]F-A85380 for human use. Appl Radiat Isot. 2005;63(4):433–5.PubMedCrossRef
14.
Schmaljohann J, Gundisch D, Minnerop M, et al. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson’s disease. Nucl Med Biol. 2006;33(3):305–9.PubMedCrossRef
15.
Kendziorra K, Wolf H, Meyer PM, et al. Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2010;38(3):515–25.PubMedCrossRef
16.
Wada T, Naito M, Kenmochi H, Tsuneki H, Sasaoka T. Chronic nicotine exposure enhances insulin-induced mitogenic signaling via up-regulation of alpha7 nicotinic receptors in isolated rat aortic smooth muscle cells. Endocrinology. 2007;148(2):790–9.PubMedCrossRef
17.
Albaugh G, Bellavance E, Strande L, Heinburger S, Hewitt CW, Alexander JB. Nicotine induces mononuclear leukocyte adhesion and expression of adhesion molecules, VCAM and ICAM, in endothelial cells in vitro. Ann Vasc Surg. 2004;18(3):302–7.PubMedCrossRef
18.
Schedel A, Thornton S, Schloss P, Kluter H, Bugert P. Human platelets express functional alpha7-nicotinic acetylcholine receptors. Arterioscler Thromb Vasc Biol. 2010;31(4):928–34.PubMedCrossRef
19.
Zhang G, Kernan KA, Thomas A, et al. A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. J Biol Chem. 2009;284(42):29050–64.PubMedCentralPubMedCrossRef
20.
Tithof PK, Elgayyar M, Schuller HM, Barnhill M, Andrews R. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine derivative, induces apoptosis of endothelial cells. Am J Physiol Heart Circ Physiol. 2001;281(5):H1946–54.PubMed
21.
Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle. 2006;5(20):2324–8.PubMedCrossRef
22.
Shin VY, Wu WK, Chu KM, et al. Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci. 2007;96(1):21–9.PubMedCrossRef
23.
Li S, Zhao T, Xin H, et al. Nicotinic acetylcholine receptor alpha7 subunit mediates migration of vascular smooth muscle cells toward nicotine. J Pharmacol Sci. 2004;94(3):334–8.PubMedCrossRef
24.
Di Luozzo G, Pradhan S, Dhadwal AK, Chen A, Ueno H, Sumpio BE. Nicotine induces mitogen-activated protein kinase dependent vascular smooth muscle cell migration. Atherosclerosis. 2005;178(2):271–7.PubMedCrossRef
25.
Kanda Y, Watanabe Y. Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. Life Sci. 2007;80(15):1409–14.PubMedCrossRef
26.
Stein JJ, Seymour KA, Maier KG, Gahtan V. The effects of nicotine on vascular smooth muscle cell chemotaxis induced by thrombospondin-1 and fibronectin. Am J Surg. 2011;202(5):545–8.PubMedCrossRef
27.
Cucina A, Fuso A, Coluccia P, Cavallaro A. Nicotine inhibits apoptosis and stimulates proliferation in aortic smooth muscle cells through a functional nicotinic acetylcholine receptor. J Surg Res. 2008;150(2):227–35.PubMedCrossRef
28.
Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7(7):833–9.PubMedCrossRef
29.
30.
Vazquez-Padron RI, Mateu D, Rodriguez-Menocal L, Wei Y, Webster KA, Pham SM. Novel role of Egr-1 in nicotine-related neointimal formation. Cardiovasc Res. 2010;88(2):296–303.PubMedCentralPubMedCrossRef
31.
Jacob T, Clouden N, Hingorani A, Ascher E. The effect of cotinine on telomerase activity in human vascular smooth muscle cells. J Cardiovasc Surg (Torino). 2009;50(3):345–9.
32.
MacLellan WR, Wang Y, Lusis AJ. Systems-based approaches to cardiovascular disease. Nat Rev Cardiol. 2012;9(3):172–84.PubMedCrossRef
33.
Cucina A, Sapienza P, Corvino V, et al. Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-beta 1. Surgery. 2000;127(3):316–22.PubMedCrossRef
34.
Cucina A, Sapienza P, Corvino V, et al. Nicotine induces platelet-derived growth factor release and cytoskeletal alteration in aortic smooth muscle cells. Surgery. 2000;127(1):72–8.PubMedCrossRef
35.
36.
Wu JC, Chruscinski A, De Jesus Perez VA, et al. Cholinergic modulation of angiogenesis: role of the 7 nicotinic acetylcholine receptor. J Cell Biochem. 2009;108(2):433–46.PubMedCentralPubMedCrossRef
37.
38.
Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation. 2003;107(4):604–11.PubMedCrossRef
39.
Antoni G, Langstrom B. Radiopharmaceuticals: molecular imaging using positron emission tomography. Handb Exp Pharmacol. 2008;(185 Pt 1):177–201.
40.
Brust P, Peters D, Deuther-Conrad W. Development of radioligands for the imaging of alpha7 nicotinic acetylcholine receptors with positron emission tomography. Curr Drug Targets. 2012;13(5):594–601.PubMedCrossRef
41.
Hagooly A, Rossin R, Welch MJ. Small molecule receptors as imaging targets. Handb Exp Pharmacol. 2008;(185 Pt 2):93–129.
42.
Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med. 2006;47(2):302–12.PubMed
43.
Spanoudaki VC, Ziegler SI. PET & SPECT instrumentation. Handb Exp Pharmacol. 2008;(185 Pt 1):53–74.
44.
45.
Xi W, Tian M, Zhang H. Molecular imaging in neuroscience research with small-animal PET in rodents. Neurosci Res. 2011;70(2):133–43.PubMedCrossRef
46.
Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci. 2010;31(9):411–7.PubMedCrossRef
47.
Heiss WD, Habedank B, Klein JC, et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med. 2004;45(11):1811–5.PubMed
48.
Lecomte R. Novel detector technology for clinical PET. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S69–85.PubMedCrossRef
49.
Sattler B, Kranz M, Starke A, Wilke S, Donat CK, Deuther-Conrad W, et al. Internal dose assessment of (−)-18F-flubatine, comparing animal model datasets of mice and piglets with first-in-human results. J Nucl Med. 2014;55(11):1885–92.
50.••
Patt M, Becker GA, Grossmann U, et al. Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (−)-[(18)F]Flubatine in humans. Nucl Med Biol. 2014;41(6):489–94. In this paper, Patt et al. demonstrate the applicability of (−)-[ 18 F]flubatine in visualization of (brain) α4β2 receptor in humans.
51.
Smits R, Fischer S, Hiller A, et al. Synthesis and biological evaluation of both enantiomers of [(18)F]flubatine, promising radiotracers with fast kinetics for the imaging of alpha4beta2-nicotinic acetylcholine receptors. Bioorg Med Chem. 2013;22(2):804–12.PubMedCrossRef
52.
Fischer S, Hiller A, Smits R, et al. Radiosynthesis of racemic and enantiomerically pure (−)-[18F]flubatine—a promising PET radiotracer for neuroimaging of alpha4beta2 nicotinic acetylcholine receptors. Appl Radiat Isot. 2013;74:128–36.PubMedCrossRef
53.
Brust P, van den Hoff J, Steinbach J. Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neurosci Bull. 2014;30(5):777–811.PubMedCrossRef
54.••
Rötering S, Deuther-Conrad W, Cumming P, et al. Imaging of alpha7 nicotinic acetylcholine receptors in brain and cerebral vasculature of juvenile pigs with [(18)F]NS14490. EJNMMI Res. 2014;4:43. In this publication, the authors show that α7-nAChR tracers, although developed for imaging in the brain, also may be used to visualize vascular acetylcholine receptor.PubMedCentralPubMedCrossRef
55.
Rötering S, Scheunemann M, Fischer S, et al. Radiosynthesis and first evaluation in mice of [(18)F]NS14490 for molecular imaging of alpha7 nicotinic acetylcholine receptors. Bioorg Med Chem. 2013;21(9):2635–42.PubMedCrossRef
56.
Bucerius J, Joe AY, Schmaljohann J, et al. Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. Clin Res Cardiol. 2006;95(2):105–9.PubMedCrossRef
57.••
Bucerius J, Manka C, Schmaljohann J, et al. Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo. JACC Cardiovasc Imaging. 2012;5(5):528–36. This is the first publication to show the feasibility of using PET imaging in vivo to detect human vascular nAChRs noninvasively.PubMedCentralPubMedCrossRef
58.
Cooke JP. Imaging vascular nicotine receptors: a new window onto vascular disease. JACC Cardiovasc Imaging. 2012;5(5):537–9.PubMedCrossRef
59.
Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology (Berlin). 2006;188(4):509–20.CrossRef
60.
Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging. 2008;29(8):1204–17.PubMedCrossRef
61.
Kadir A, Darreh-Shori T, Almkvist O, Wall A, Langstrom B, Nordberg A. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berlin). 2007;191(4):1005–14.CrossRef
62.
Nordberg A, Hartvig P, Lilja A, et al. Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect. 1990;2(3):215–24.PubMedCrossRef
63.
Pichika R, Easwaramoorthy B, Collins D, et al. Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol. 2006;33(3):295–304.PubMedCrossRef
64.
Pichika R, Easwaramoorthy B, Christian BT, et al. Nicotinic alpha4beta2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'-18F-fluoropropyl)pyridine (18F-nifzetidine). Nucl Med Biol. 2011;38(8):1183–92.PubMedCentralPubMedCrossRef
65.
Pichika R, Kuruvilla SA, Patel N, et al. Nicotinic alpha4beta2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3'-(1)(8)F-fluoropropyl)pyridine ((1)(8)F-Nifrolene) using PET. Nucl Med Biol. 2012;40(1):117–25.PubMedCentralPubMedCrossRef
66.
Mukhin AG, Kimes AS, Chefer SI, et al. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med. 2008;49(10):1628–35.PubMedCentralPubMedCrossRef
67.
Staley JK, van Dyck CH, Weinzimmer D, et al. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med. 2005;46(9):1466–72.PubMed
68.
Ogawa M, Tsukada H, Hatano K, Ouchi Y, Saji H, Magata Y. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Biol Pharm Bull. 2009;32(3):337–40.PubMedCrossRef
69.
Valette H, Xiao Y, Peyronneau MA, et al. 18F-ZW-104: a new radioligand for imaging neuronal nicotinic acetylcholine receptors—in vitro binding properties and PET studies in baboons. J Nucl Med. 2009;50(8):1349–55.PubMedCrossRef
70.
Gao Y, Kuwabara H, Spivak CE, et al. Discovery of (−)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. J Med Chem. 2008;51(15):4751–64.PubMedCrossRef
71.
Horti AG, Gao Y, Kuwabara H, Dannals RF. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. 2008;86(15–16):575–84.
72.
Wong DF, Kuwabara H, Kim J, et al. PET imaging of high-affinity alpha4beta2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics. J Nucl Med. 2013;54(8):1308–14.PubMedCrossRef
73.
Meyer PM, Tiepolt S, Barthel H, Hesse S, Sabri O. Radioligand imaging of alpha4beta2* nicotinic acetylcholine receptors in Alzheimer’s disease and Parkinson’s disease. Q J Nucl Med Mol Imaging. 2014;58(4):376–86.PubMed
74.
Villemagne VL, Horti A, Scheffel U, et al. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J Nucl Med. 1997;38(11):1737–41.PubMed
75.
Horti AG, Chefer SI, Mukhin AG, et al. 6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. Life Sci. 2000;67(4):463–9.PubMedCrossRef
76.
Horti AG, Ravert HT, Gao Y, et al. Synthesis and evaluation of new radioligands [(11)C]A-833834 and [(11)C]A-752274 for positron-emission tomography of alpha7-nicotinic acetylcholine receptors. Nucl Med Biol. 2013;40(3):395–402.PubMedCentralPubMedCrossRef
77.
Toyohara J, Ishiwata K, Sakata M, et al. In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys. PLoS One. 2010;5(2):e8961.PubMedCentralPubMedCrossRef
78.
Gao Y, Ravert HT, Valentine H, et al. 5-(5-(6-[(11)C]methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)-1H-indole as a potential PET radioligand for imaging cerebral alpha7-nAChR in mice. Bioorg Med Chem. 2012;20(12):3698–702.PubMedCentralPubMedCrossRef
79.
Ogawa M, Nishiyama S, Tsukada H, et al. Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor alpha7 subtype. Nucl Med Biol. 2010;37(3):347–55.PubMedCrossRef
80.
Sakata M, Wu J, Toyohara J, et al. Biodistribution and radiation dosimetry of the alpha7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in humans. Nucl Med Biol. 2011;38(3):443–8.PubMedCrossRef
81.
Wu J, Toyohara J, Tanibuchi Y, et al. Pharmacological characterization of [(125)I]CHIBA-1006 binding, a new radioligand for alpha7 nicotinic acetylcholine receptors, to rat brain membranes. Brain Res. 2010;1360:130–7.PubMedCrossRef
82.
Hashimoto K, Ishima T, Fujita Y, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry. 2008;63(1):92–7.PubMedCrossRef
83.
Toyohara J, Sakata M, Wu J, et al. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med. 2009;23(3):301–9.PubMedCrossRef
84.
Deuther-Conrad W, Fischer S, Hiller A, et al. Assessment of alpha7 nicotinic acetylcholine receptor availability in juvenile pig brain with [(1)(8)F]NS10743. Eur J Nucl Med Mol Imaging. 2011;38(8):1541–9.PubMedCrossRef
85.
Deuther-Conrad W, Fischer S, Hiller A, et al. Molecular imaging of alpha7 nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743. Eur J Nucl Med Mol Imaging. 2009;36(5):791–800.PubMedCrossRef
86.
Wong DF, Kuwabara H, Pomper M, et al. Human brain imaging of alpha7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy. Mol Imaging Biol. 2014;16(5):730–8.PubMedCrossRef
87.
Gao Y, Kellar KJ, Yasuda RP, et al. Derivatives of dibenzothiophene for positron emission tomography imaging of alpha7-nicotinic acetylcholine receptors. J Med Chem. 2013;56(19):7574–89.PubMedCrossRef
88.
Ettrup A, Mikkelsen JD, Lehel S, et al. 11C-NS14492 as a novel PET radioligand for imaging cerebral alpha7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med. 2011;52(9):1449–56.PubMedCrossRef
89.
Rötering S, Deuther-Conrad W, Cumming P, et al. Imaging of α7 nicotinic acetylcholine receptors in brain and cerebral vasculature of juvenile pigs with [18F] NS14490. EJNMMI Res. 2014;4:43.PubMedCentralPubMedCrossRef
Metadata
Title
PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis
Authors
Matthias Bauwens
Felix M. Mottaghy
Jan Bucerius
Publication date
01-08-2015
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 8/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0614-8

Other articles of this Issue 8/2015

Current Cardiology Reports 8/2015 Go to the issue

Peripheral Vascular Disease (MR Jaff, Section Editor)

Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Pacing the Heart with Genes: Recent Progress in Biological Pacing

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Management of Ventricular Arrhythmias in Patients with Mechanical Ventricular Support Devices

Peripheral Vascular Disease (MR Jaff, Section Editor)

Nonatherosclerotic PAD: Approach to Exertional Pain in the Lower Extremities

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits